PMID- 35596704
OWN - NLM
STAT- MEDLINE
DCOM- 20220825
LR  - 20220825
IS  - 1440-1827 (Electronic)
IS  - 1320-5463 (Linking)
VI  - 72
IP  - 8
DP  - 2022 Aug
TI  - Update of pathological diagnosis of pleural mesothelioma using genomic-based 
      morphological techniques, for both histological and cytological investigations.
PG  - 389-401
LID - 10.1111/pin.13235 [doi]
AB  - As more than 80% of pleural mesothelioma (PM) cases start with pleural effusions, 
      diagnosis with effusion smear cytology or pleural biopsy is important. For 
      diagnosing PM, a three-step approach is used: (1) detecting atypical cells; (2) 
      verifying their mesothelial origin using immunohistochemistry (IHC); and (3) 
      discriminating PM from benign mesothelial proliferations (BMP). The third step is 
      critical for diagnosing early lesions. In small biopsy or cytologic specimens in 
      which tumor cell fat invasion cannot be assessed, genomic-based assays, including 
      IHC-detected BAP1 loss and fluorescence in situ hybridization (FISH)-detected 
      homozygous deletion (HD) of CDKN2A/p16, are effective for differentiation. Both 
      BAP1 IHC and CDKN2A FISH can equally be applied to histologic and cytologic 
      specimens, with 100% specificity in discriminating PM from BMP. We found that 
      methylthioadenosine phosphorylase (MTAP) loss as detected by IHC could serve as a 
      feasible alternative in tissue and cytologic preparations for CDKN2A FISH. 
      However, a combination including FISH was still most effective: the addition of 
      NF2 FISH to CDKN2A FISH and BAP1 IHC yielded a greater sensitivity of close to 
      100% in diagnosing PM tissues. Although IHC is more feasible than FISH, owing to 
      remaining challenges in data interpretation, caution and familiarity are 
      warranted when diagnosing PM.
CI  - (c) 2022 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
FAU - Nabeshima, Kazuki
AU  - Nabeshima K
AUID- ORCID: 0000-0002-0691-1222
AD  - Department of Pathology, Fukuoka University School of Medicine and Hospital, 
      Fukuoka, Japan.
FAU - Hamasaki, Makoto
AU  - Hamasaki M
AUID- ORCID: 0000-0002-2481-3888
AD  - Department of Pathology, Fukuoka University School of Medicine and Hospital, 
      Fukuoka, Japan.
FAU - Kinoshita, Yoshiaki
AU  - Kinoshita Y
AD  - Department of Pathology, Fukuoka University School of Medicine and Hospital, 
      Fukuoka, Japan.
FAU - Matsumoto, Shinji
AU  - Matsumoto S
AD  - Department of Pathology, Fukuoka University School of Medicine and Hospital, 
      Fukuoka, Japan.
FAU - Sa-Ngiamwibool, Prakasit
AU  - Sa-Ngiamwibool P
AUID- ORCID: 0000-0002-5090-6594
AD  - Department of Pathology, Fukuoka University School of Medicine and Hospital, 
      Fukuoka, Japan.
AD  - Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kean, 
      Thailand.
LA  - eng
GR  - #200598/Grant from the Ministry of the Environment/
GR  - Grant from the Research Center for Advanced Molecular Medicine, Fukuoka 
      University/
GR  - #19K07451/Grants-in-Aid for Scientific Research from the Japanese Society for the 
      Promotion of Science/
PT  - Journal Article
PT  - Review
DEP - 20220521
PL  - Australia
TA  - Pathol Int
JT  - Pathology international
JID - 9431380
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics
MH  - Genomics
MH  - Homozygote
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/pathology
MH  - *Mesothelioma/diagnosis/genetics/pathology
MH  - *Mesothelioma, Malignant/diagnosis
MH  - *Pleural Neoplasms/diagnosis/genetics/pathology
MH  - Sequence Deletion
MH  - Tumor Suppressor Proteins/genetics
MH  - Ubiquitin Thiolesterase/genetics
OTO - NOTNLM
OT  - BAP1
OT  - CDKN2A
OT  - FISH
OT  - MTAP
OT  - NF2
OT  - cytology
OT  - histology
OT  - pleural mesothelioma
EDAT- 2022/05/22 06:00
MHDA- 2022/08/26 06:00
CRDT- 2022/05/21 08:13
PHST- 2022/01/20 00:00 [received]
PHST- 2022/04/28 00:00 [accepted]
PHST- 2022/05/22 06:00 [pubmed]
PHST- 2022/08/26 06:00 [medline]
PHST- 2022/05/21 08:13 [entrez]
AID - 10.1111/pin.13235 [doi]
PST - ppublish
SO  - Pathol Int. 2022 Aug;72(8):389-401. doi: 10.1111/pin.13235. Epub 2022 May 21.